SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Cardiovascular Pharmacology and Therapeutics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Fossum, T. W.
Right arrow Articles by Carney, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fossum, T. W.
Right arrow Articles by Carney, D. H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

TP508 (Chrysalin®) Reverses Endothelial Dysfunction and Increases Perfusion and Myocardial Function in Hearts With Chronic Ischemia

Theresa W. Fossum, DVM, PhD

Michael E. DeBakey Institute, Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Texas A&M University, College Station, Texas

Barbara Olszewska-Pazdrak, MD

Therapeutic Peptide Development Laboratory, Department of Biochemistry and Molecular Biology, the University of Texas Medical Branch, Galveston, Texas

Michelle M. Mertens, DVM

Michael E. DeBakey Institute, Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Texas A&M University, College Station, Texas

Lori A. Makarski, DVM

Michael E. DeBakey Institute, Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Texas A&M University, College Station, Texas

Matthew W. Miller, DVM, MS

Michael E. DeBakey Institute, Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Texas A&M University, College Station, Texas

Travis W. Hein, PhD

Departments of Surgery and Ophthalmology, Scott and White Memorial Hospital, Temple, Texas

Lih Kuo, PhD

Department of Systems Biology and Translational Medicine, Texas A&M Health Science Center, Temple, Texas

Fred Clubb, DVM, PhD

Department of Pathobiology, College of Veterinary Medicine, Texas A&M University, College Station, Texas

Gerald M. Fuller, PhD

Department of Cell Biology, University of Alabama, Birmingham, Alabama

Darrell H. Carney, PhD

Therapeutic Peptide Development Laboratory, Department of Biochemistry and Molecular Biology, the University of Texas Medical Branch, Galveston, Texas, dcarney{at}utmb.edu

Endothelial dysfunction (ED) is characterized by impaired nitric oxide (NO) signaling, decreased NO-dependent vasodilatation, increased vascular inflammation, and diminished response to angiogenic factors. TP508 (Chrysalin®), an angiogenic tissue repair peptide, was tested for potential effects on myocardial revascularization and ED using a porcine model of chronic myocardial ischemia. TP508 increased perfusion in ischemic regions up to16-fold (P < .02) and doubled myocardial wall thickening (P < .02) relative to placebo controls. Ischemic arterioles exhibited impaired NO-mediated vasodilation and diminished NO production. TP508 reversed ischemic effects, increasing NO-mediated vasodilation (P < .05), endothelial nitric oxide synthase (eNOS) expression, and NO production. In human endothelial cells, TP508 stimulated eNOS activation (1.84 ± 0.2-fold; P < .02), increased NO production (85 ± 18%; P < .02), and prevented hypoxia-induced eNOS downregulation (P < .01). Thus, TP508 reverses ED both in porcine ischemic hearts and cultured human endothelial cells. These results suggest potential therapeutic benefit of TP508 in myocardial revascularization and treatment of ED-related diseases.

Key Words: thrombin peptide TP508 • myocardial revascularization • endothelial dysfunction • nitric oxide • human coronary artery endothelial cells

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 13, No. 3, 214-225 (2008)
DOI: 10.1177/1074248408321468


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
R. M. Osipov, M. P. Robich, J. Feng, R. T. Clements, Y. Liu, H. P. Glazer, J. Wagstaff, C. Bianchi, and F. W. Sellke
Effect of thrombin fragment (TP508) on myocardial ischemia-reperfusion injury in hypercholesterolemic pigs
J Appl Physiol, June 1, 2009; 106(6): 1993 - 2001.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
B. Olszewska-Pazdrak, T. W. Hein, P. Olszewska, and D. H. Carney
Chronic hypoxia attenuates VEGF signaling and angiogenic responses by downregulation of KDR in human endothelial cells
Am J Physiol Cell Physiol, May 1, 2009; 296(5): C1162 - C1170.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. M. Osipov, C. Bianchi, R. T. Clements, J. Feng, Y. Liu, S.-H. Xu, M. P. Robich, J. Wagstaff, and F. W. Sellke
Thrombin Fragment (TP508) Decreases Myocardial Infarction and Apoptosis After Ischemia Reperfusion Injury.
Ann. Thorac. Surg., March 1, 2009; 87(3): 786 - 793.
[Abstract] [Full Text] [PDF]



Advertisement